Immunogenicity Study of S-OIV H1N1 Influenza Vaccine

Status Active, not recruiting

Clinical Trial Summary

The primary immunogenicity objective is to assess the antibody response and T-cell response of split-virion inactivated A (H1N1) vaccine. Participants will include up to 20 healthy persons of age 20 and older who have no history of novel influenza H1N1 2009 infection in latest 3 months or novel influenza H1N1 2009 vaccination. This is a randomized study in healthy males and non-pregnant females, aged 20 years and older. All subjects will be stratified into 1 dose group (15mcg per dose), and will receive intramuscular influenza H1N1 vaccine. The H1N1 vaccine will be administered at Day 0 and Day 21. On Day 0, Day 10, Day 21, Day 28, Day 35 and Day 42 after first vaccination (Day 0), the immunogenicity testing will be manipulated. The antibody response of immunogenicity testing will be hemagglutination inhibiting (HAI) on serum. The T-cell response will be interferon-gamma ELISPOT assay and Tetramer staining using PBMCs.

Clinical Trial Description

In 2009, a novel swine-origin influenza A/H1N1 virus was identified as a significant cause of febrile respiratory illnesses in North America. It rapidly spread to many countries around the world, which soon meets the World Health Organization (WHO) criteria for a pandemic. Data from several clinical trails with the split-virion inactivated S-OIV vaccine suggest that the vaccine stimulated strong specific antibody against S-OIV. However, the is no T-cell response data after the vaccination. In addition, we do not know S-OIV specific cellular immunity level of the population. These facts indicate the need to assess both the antibody response and T-cell response after the vaccination of the split-virion inactivated S-OIV vaccine. The primary immunogenicity objective is to assess the antibody response and T-cell response of split-virion inactivated A (H1N1) vaccine. Participants will contain only one age group, including up to 20 healthy persons of age 20 and older who have no history of novel influenza H1N1 2009 infection in latest 3 months or novel influenza H1N1 2009 vaccination. This is a randomized study in healthy males and non-pregnant females. All subjects will be stratified into 1 dose group (15mcg per dose), and will receive intramuscular influenza H1N1 vaccine. The H1N1 vaccine will be administered at Day 0 and Day 21. On Day 0, Day 10, Day 21, Day 28, Day 35 and Day 42 after first vaccination (Day 0), the immunogenicity testing will be manipulated. The antibody response of immunogenicity testing will be hemagglutination inhibiting (HAI) on serum. The T-cell response will be interferon-gamma ELISPOT assay and Tetramer staining using PBMCs. ;

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01096225
Study type	Observational
Source	Chinese Academy of Sciences
Contact
Status	Active, not recruiting
Phase	N/A
Start date	March 2010
Completion date	August 2010

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01690637` - Panama and El Salvador Children's Oseltamivir Study	Phase 4
Completed	`NCT03572491` - Preventive Effectiveness, Safety and Immunogenicity of a Allantoic Split Inactivated Seasonal Influenza Vaccine	Phase 3
Recruiting	`NCT04487041` - Tfh Dysfunction in HIV and Aging	Phase 4
Completed	`NCT02387294` - Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents	Phase 3
Completed	`NCT02600585` - Post-Marketing Observational Study of Safety Following Vaccination With Flublok® Compared to Licensed IIV in Adults	N/A
Completed	`NCT02398097` - Conventional Vaccine and Intradermal Vaccine Among HIV-infected Young Subjects	Phase 4
Completed	`NCT01511744` - Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine	Phase 4
Completed	`NCT01342796` - Humoral and Cell Mediated Immunity and Safety of MF59C.1-adjuvanted Subunit Influenza Vaccine or a Conventional Subunit Influenza Vaccine in Previously Unvaccinated Healthy Subjects	Phase 2
Completed	`NCT01677702` - Study of Yili Lactoferrin ShuHua Milk in the Improvement of Human Immunization	N/A
Completed	`NCT00880659` - Bangladesh Secondary Transmission Handwashing Protocol	Phase 2
Completed	`NCT01879540` - Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age	Phase 2
Completed	`NCT01879553` - Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above	Phase 2
Completed	`NCT01651104` - Safety and Immunogenicity of a Trivalent Influenza Vaccine When Administered to Elderly Subjects	Phase 2
Completed	`NCT01636102` - Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above	Phase 2
Completed	`NCT03448705` - Safety of 4Fluart ID Suspension for Injection in Adult Subjects	Phase 1
Completed	`NCT02478905` - Transmission of Influenza Virus From Asymptomatic Healthcare Workers and Inpatients in the Acute Care Hospital Setting	N/A
Recruiting	`NCT04431050` - Evaluation of a Single Use Point of Care Device for the Diagnosis of Respiratory Pathogens
Completed	`NCT01568788` - Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine	N/A
Completed	`NCT05155319` - Universal Influenza A Vaccine in Healthy Adults	Phase 1
Completed	`NCT01885117` - Safety and Immunogenicity of One Dose of Seasonal Trivalent Influenza Virus Vaccine (TIVf, Purified Surface Antigen, Inactivated, Egg Derived) in Adults, Aged 18 Years and Above	Phase 3